Mireille IRABE
Saint-Pierre, 97432, France
Location status: Recruiting
Location contact
Mireille IRABE
CONTACT
NCT Number: NCT05898009
In mainland France, breast cancer is the most common cancer in women, with an estimated incidence of over 58,000 new cases. Even if breast cancer is a cancer with a good prognosis, it is responsible for more than 12,000 deaths per year (first cause of death by cancer in women in France).
Breast cancer is a multifactorial disease, which results from the interaction between environmental, lifestyle, hormonal and genetic risk factors.
In Reunion, more than 400 cases of breast cancer are diagnosed annually. As in mainland France, it is by far the most common cancer in Reunionese women, and its incidence continues to increase significantly since the age-standardized incidence rate increased by 28% between 2007 and 2017 to establish at 64.2/100,000 AP.
Two studies carried out in patients carrying mutations in the breast-ovary predisposition genes in Reunion, showed that more than 50% of patients carrying BRCA mutation have a mutation specific to the Reunion population on the BRCA2 gene.
These two studies, which confirm the genetic specificities of Reunion already described in other pathologies (Mucoviscidosis or Friedreich's Ataxia), suggest that this mutation could have a significant frequency in patients with breast cancer. Thus, evaluating the prevalence of this mutation in patients with breast cancer in Réunion would make it possible to adapt the indications for access to the oncogenetics consultation and the associated preventive measures
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Saint-Pierre, 97432, France
Location status: Recruiting
Mireille IRABE
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
blood sample
Time frame: inclusion day
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire de la Réunion
Other
Acronym: CanSeR-OGen
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06395519
Adnexal Diseases, Advanced or Metastatic Solid Tumors
Phoenix, Arizona, United States
View Trial DetailsNCT06380660
Adnexal Diseases, BRCA1 Mutation
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT03702309
Adnexal Diseases, BRCA1 Mutation
Toronto, Ontario, Canada
View Trial DetailsNCT06488378
BRCA1 Mutation, BRCA2 Mutation
Boston, Massachusetts, United States
View Trial Details